CStone Pharmaceuticals Profit Margin

CStone Pharmaceuticals (CSPHF) currently reports a profit margin of -109.78% as of June 2026. That compares with -95.2% in the prior-year period — down 15.3% year over year. That is below the Healthcare sector average of 9.71%. Use the charts on this page to explore CStone Pharmaceuticals's profit margin history and peer comparisons.

CStone Pharmaceuticals's profit margin decreased from -95.2% to -109.78% — a 15.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CStone Pharmaceuticals's profit margin of -109.78% is lower than the Healthcare sector average of 9.71%. That is roughly 1231.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but CStone Pharmaceuticals's current -109.78% should be judged against Healthcare norms (sector average: 9.71%) and against CSPHF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -109.78%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.71%. From there, open related valuation or income-statement pages for CStone Pharmaceuticals, and consider following CSPHF for alerts when major investors trade the stock.